Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560638 · ClinicalTrials.gov registry record · Phase 2
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT00560638: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT00560638 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 119 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00560638, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
Interventions
- DRUG loteprednol etabonate ophthalmic suspension, 0.5%
- DRUG vehicle of loteprednol etabonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
What the finished NCT00560638 record still lists
NCT00560638 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (11% lower).
The record links to 0 conditions, and to 2 interventions - of which loteprednol etabonate ophthalmic suspension, 0.5% is the first listed.
NCT00560638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00560638 about?
NCT00560638 is a clinical study titled "Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye". This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabona...
What is the current status of trial NCT00560638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2005-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00560638?
The interventions under investigation include: loteprednol etabonate ophthalmic suspension, 0.5% (DRUG), vehicle of loteprednol etabonate (DRUG).
Who is sponsoring clinical trial NCT00560638?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00560638's enrollment target sits among peer trials
119 618th of 2000 higher than 1,383 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia